Delivery Order 36F79720D0189-36C26123F0645
Award Date
9/25/23
Potential Completion Date
11/10/23
Potential Value
$13K
Federal Agency
Veterans Integrated Service Network 21
Awardee
Incyte Corporation
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Talleyville, DE 19803, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 awarded Incyte Corporation a $12,725.23 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule contract to provide 13.5mg tabs of pemigatinib (Pemazyre). Performance will occur in Talleyville, Delaware by the fixed price completion date of November 15, 2020. The delivery order was awarded on October 29, 2020 with no set-aside designation specified. Pemazyre will be...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 1 awarded a $12,725.23 delivery order to Incyte Corporation under the Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB). The firm fixed price order is for PEMAZYRE 9 MG tablets to fulfill requirements through September 30th, 2022. Place of performance will be Incyte Corporation's location in West Chester Township, Ohio. No set-aside designation was applied to this order to...
Incyte Corporation was awarded a $12,725.23 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12. The delivery order, which has no set aside designation and completion date of October 30, 2020, is for the provision of PEMAZYRE to treat patients. The firm fixed price order was awarded on October 5, 2020 under Incyte's master GSA Schedule contract vehicle. The place...
Incyte Corporation was awarded a $13,290.97 delivery order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 to supply Pemigatinib tablets. The order was issued against Incyte's Pharmaceuticals and Drugs Federal Supply Schedule contract to fulfill a request for Pemazyre, an anti-cancer medication, with delivery to occur by March 2024. Incyte holds a Blanket Purchase Agreement valued at $3.75 million and a ten-year Federal Supply...
Incyte Corporation has been awarded a $12,811.62 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21. The firm fixed price order is for PEMIGATINIB/PEMAZYRE 9MG TAB to be delivered to a location in Fresno, California by May 22, 2023. No set-aside designation was applied to this order placed under GSA Schedule FSS-61-IB to supply pharmaceutical products and drugs in...
Incyte Corporation was awarded a $25,450.46 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 1. The order, which has a completion date of October 31, 2022, is for the drug PEMAZYRE to be delivered to a location in West Chester Township, Ohio. No set-aside designation was used for this award issued under master GSA Schedule contract FSS-61-IB. The pricing is firm...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 16 awarded a $40,668.40 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule to Genzyme Corporation for emergency Caprelsa (vandetanib) medication. Genzyme Therapeutics Division, a division of Sanofi Genzyme, will provide the medication on a firm fixed price basis, with completion by October 30, 2020. The delivery order was awarded on May 28, 2020 under GSA Schedule...
The Department of Veterans Affairs Veterans Health Administration awarded a $678,720 delivery order to Emergent Devices Inc. under the Pharmaceuticals and Drugs Federal Supply Schedule contract. The order is to replenish pharmaceutical inventory items to support clinical operations for VHA Network 12. Performance will take place in Wayne, Pennsylvania over a period of six days from April 9-15, 2021. The firm fixed price order was awarded on a non-set aside basis to Emergent Devices Inc. as the...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 10 awarded a $360,826.88 firm fixed price delivery order against the Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., with parent company Lantheus Holdings, Inc. The order is for the drug PYLARIFY and has a period of performance through January 15, 2025 with no set-aside designation used. PYLARIFY will likely be...
The Department of Veterans Affairs Veterans Health Administration awarded a $678,720 delivery order to Emergent Devices Inc. under the company's Pharmaceuticals and Drugs Federal Supply Schedule contract. The order calls for Emergent Devices to supply pharmaceutical items to meet the clinical needs of VA's Veterans Integrated Service Network 12, located in Wayne, Pennsylvania, with performance from December 4-11, 2020. No subcontractors or set aside designations were identified. This order...